|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-6-13
|
|
pubmed:abstractText |
The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving lenograstim vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes. 5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy. The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:BudaGabrieleG,
pubmed-author:CangialosiClotildeC,
pubmed-author:De PaolisMaria RosariaMR,
pubmed-author:Di RenzoNicolaN,
pubmed-author:MarturanoEmerenzianaE,
pubmed-author:MauroElisaE,
pubmed-author:MazzaPatrizioP,
pubmed-author:MiloneGiuseppeG,
pubmed-author:OrciuoloEnricoE,
pubmed-author:PastoreDomenicoD,
pubmed-author:PetriniMarioM,
pubmed-author:PietrantuonoGiuseppeG,
pubmed-author:SpecchiaGiorginaG
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
899-903
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21134693-Adjuvants, Immunologic,
pubmed-meshheading:21134693-Adolescent,
pubmed-meshheading:21134693-Adult,
pubmed-meshheading:21134693-Aged,
pubmed-meshheading:21134693-Antineoplastic Agents, Alkylating,
pubmed-meshheading:21134693-Combined Modality Therapy,
pubmed-meshheading:21134693-Cyclophosphamide,
pubmed-meshheading:21134693-Female,
pubmed-meshheading:21134693-Fever,
pubmed-meshheading:21134693-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:21134693-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:21134693-Humans,
pubmed-meshheading:21134693-Incidence,
pubmed-meshheading:21134693-Male,
pubmed-meshheading:21134693-Middle Aged,
pubmed-meshheading:21134693-Multiple Myeloma,
pubmed-meshheading:21134693-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:21134693-Prospective Studies,
pubmed-meshheading:21134693-Recombinant Proteins,
pubmed-meshheading:21134693-Survival Rate,
pubmed-meshheading:21134693-Transplantation, Autologous,
pubmed-meshheading:21134693-Treatment Outcome,
pubmed-meshheading:21134693-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
|
|
pubmed:affiliation |
Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Pisa, Italy. orci@sssup.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
